Função sistólica do ventrículo esquerdo pela ecocardiografia em crianças e adolescentes com osteossarcoma tratados com doxorrubicina com e sem dexrazoxane
Autor(a) principal: | |
---|---|
Data de Publicação: | 2006 |
Outros Autores: | , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Repositório Institucional da UNIFESP |
Texto Completo: | http://dx.doi.org/10.1590/S0066-782X2006001900013 http://repositorio.unifesp.br/handle/11600/3400 |
Resumo: | OBJECTIVE: To evaluate left ventricular (LV) systolic function by means of echocardiography in patients with osteosarcoma treated with doxorubicin alone or in combination with dexrazoxane. METHODS: The study analyzed 55 patients with osteosarcoma, with or without metastasis, undergoing a six-cycle chemotherapy regimen of doxorubicin, who were divided into two groups according to dexrazoxane use. Group I: Thirty-seven patients who did not receive dexrazoxane (28 males, average age 15.4 years). Group II: Eighteen patients who did receive dexrazoxane (15 males, average age 15.1 years). Four echocardiographic evaluations were performed: 1) before the beginning of the chemotherapy (initial evaluation); 2) up to two weeks after the third cycle; 3) up to two weeks after the fifth cycle; and 4) up to four weeks after the sixth cycle of chemotherapy (final evaluation). The left ventricular systolic function was assessed by the fractional percentage of systolic shortening (FS%) on echocardiography. Alterations in the contractile function or cardiac toxicity were defined as FS% values equal to or lower than 29%, and/or by a drop in FS% by an absolute value equal to or greater than 10 units of the baseline value of each patient. RESULTS: No significant difference as to age, gender, and race was observed between the groups. The cumulative dose of doxorubicin was significantly higher in group II throughout all phases of the treatment: 174 x 203 mg/m²; 292 x 338 mg/m² and 345 x 405 mg/² (p < 0.0001). According to previously established criteria, the incidence of LV systolic dysfunction was not significantly different (p=0.248) between patients in group I (18.92%) and patients in group II (11.1%). The variance analysis with repeated measurements did not show significant differences in the means of fractional percentage of systolic percentage (FS%) throughout the study (p=0.967). However, a significant difference (p=0.029) was observed between the FS% means in groups I and II at evaluations 2 (35.67 x 37.21%), 3 (34.95 x 38.47%) and 4 (35.26 x 38.22%). CONCLUSION: Data in this study show that in patients with osteosarcoma treated with doxorubicin alone or combined with dexrazoxane, the LV systolic function, as assessed by the fractional percentage of systolic shortening mean, showed a better performance in the group that received dexrazoxane. On the other hand, the occurrence of systolic dysfunction was similar in both groups. |
id |
UFSP_1ff67eec4540c56933380a6c0badc05b |
---|---|
oai_identifier_str |
oai:repositorio.unifesp.br/:11600/3400 |
network_acronym_str |
UFSP |
network_name_str |
Repositório Institucional da UNIFESP |
repository_id_str |
3465 |
spelling |
Função sistólica do ventrículo esquerdo pela ecocardiografia em crianças e adolescentes com osteossarcoma tratados com doxorrubicina com e sem dexrazoxaneLeft ventricular systolic function assessed by echocardiography in children and adolescents with osteosarcoma treated with doxorubicin alone or in combination with dexrazoxaneLeft ventricular functionechocardiographyosteosarcomadoxorubicindexrazoxaneFunção ventricular esquerdaecocardiografiaosteossarcomadoxorrubicinadexrazoxaneOBJECTIVE: To evaluate left ventricular (LV) systolic function by means of echocardiography in patients with osteosarcoma treated with doxorubicin alone or in combination with dexrazoxane. METHODS: The study analyzed 55 patients with osteosarcoma, with or without metastasis, undergoing a six-cycle chemotherapy regimen of doxorubicin, who were divided into two groups according to dexrazoxane use. Group I: Thirty-seven patients who did not receive dexrazoxane (28 males, average age 15.4 years). Group II: Eighteen patients who did receive dexrazoxane (15 males, average age 15.1 years). Four echocardiographic evaluations were performed: 1) before the beginning of the chemotherapy (initial evaluation); 2) up to two weeks after the third cycle; 3) up to two weeks after the fifth cycle; and 4) up to four weeks after the sixth cycle of chemotherapy (final evaluation). The left ventricular systolic function was assessed by the fractional percentage of systolic shortening (FS%) on echocardiography. Alterations in the contractile function or cardiac toxicity were defined as FS% values equal to or lower than 29%, and/or by a drop in FS% by an absolute value equal to or greater than 10 units of the baseline value of each patient. RESULTS: No significant difference as to age, gender, and race was observed between the groups. The cumulative dose of doxorubicin was significantly higher in group II throughout all phases of the treatment: 174 x 203 mg/m²; 292 x 338 mg/m² and 345 x 405 mg/² (p < 0.0001). According to previously established criteria, the incidence of LV systolic dysfunction was not significantly different (p=0.248) between patients in group I (18.92%) and patients in group II (11.1%). The variance analysis with repeated measurements did not show significant differences in the means of fractional percentage of systolic percentage (FS%) throughout the study (p=0.967). However, a significant difference (p=0.029) was observed between the FS% means in groups I and II at evaluations 2 (35.67 x 37.21%), 3 (34.95 x 38.47%) and 4 (35.26 x 38.22%). CONCLUSION: Data in this study show that in patients with osteosarcoma treated with doxorubicin alone or combined with dexrazoxane, the LV systolic function, as assessed by the fractional percentage of systolic shortening mean, showed a better performance in the group that received dexrazoxane. On the other hand, the occurrence of systolic dysfunction was similar in both groups.OBJETIVO: Avaliar o comportamento da função sistólica do ventrículo esquerdo (VE) pela ecocardiografia em pacientes com osteossarcoma tratados com doxorrubicina com e sem dexrazoxane. MÉTODOS: Foram estudados 55 pacientes com osteossarcoma com ou sem metástase submetidos à quimioterapia (QT) com seis ciclos de doxorrubicina, divididos em dois grupos, conforme o uso de dexrazoxane. Grupo I: 37 pacientes, os quais receberam dexrazoxane (28 do sexo masculino, com média de idade de 15,4 anos). Grupo II: 18 pacientes, que não receberam dexrazoxane (15 do sexo masculino, com média de idade de 15,1 anos). Foram realizadas quatro avaliações ecocardiográficas: 1) antes do início da QT (avaliação inicial); 2) até duas semanas após o terceiro ciclo; 3) até duas semanas após o quinto ciclo e 4) até quatro semanas após o sexto ciclo da QT (avaliação final). A função sistólica do VE foi avaliada pela porcentagem de encurtamento (PE) com o ecocardiograma. Alteração da função contrátil ou toxicidade miocárdica foi definida com valores de PE iguais ou inferiores a 29% e/ou diminuição da PE, em valor absoluto, igual ou superior a 10 unidades do valor inicial de cada paciente. RESULTADOS: Não houve diferença significativa entre os grupos quanto à idade, sexo e raça. A dose cumulativa de doxorrubicina foi significantemente maior no grupo II em todas as fases do tratamento: 174 x 203 mg/m²; 292 x 338 mg/m² e 345 x 405 mg/² (p < 0,0001). A ocorrência de disfunção sistólica do VE, de acordo com os critérios previamente definidos, foi de sete indivíduos no grupo I (18,92%) e de dois no grupo II (11,1%), diferença não significativa (p=0,248). A análise de variância com medidas repetidas não mostrou diferença significativa nas médias da PE ao longo do período de estudo (p=0,967). Entretanto foi encontrada diferença significativa (p=0,029) entre as médias da PE dos grupos I e II nas avaliações 2 (35,67 x 37,21%), 3 (34,95 x 38,47%) e 4 (35,26 x 38,22%). CONCLUSÃO: Os dados do presente estudo indicam que, nos pacientes com osteossarcoma ltratados com doxorrubicina com e sem dexrazoxane, a função sistólica do VE, avaliada pela média da porcentagem de encurtamento, apresentou melhor desempenho no grupo que recebeu a administração de dexrazoxane. A ocorrência de disfunção sistólica, porém, foi semelhante entre os dois grupos de pacientes.Universidade Federal de São Paulo (UNIFESP)Escola Paulista de Medicina Instituto de Oncologia PediátricaUNIFESP, EPM Instituto de Oncologia PediátricaSciELOSociedade Brasileira de Cardiologia - SBCUniversidade Federal de São Paulo (UNIFESP)Matos Neto, Ranulfo Pinheiro de [UNIFESP]Petrilli, Antonio Sergio [UNIFESP]Silva, Célia Maria Campos [UNIFESP]Campos Filho, Orlando [UNIFESP]Oporto, Victor Manuel [UNIFESP]Gomes, Lourdes de Fátima Gonçalves [UNIFESP]Paiva, Marcelo Goulart [UNIFESP]Carvalho, Antonio Carlos [UNIFESP]Moisés, Valdir Ambrósio [UNIFESP]2015-06-14T13:36:34Z2015-06-14T13:36:34Z2006-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion763-771application/pdfhttp://dx.doi.org/10.1590/S0066-782X2006001900013Arquivos Brasileiros de Cardiologia. Sociedade Brasileira de Cardiologia - SBC, v. 87, n. 6, p. 763-771, 2006.10.1590/S0066-782X2006001900013S0066-782X2006001900013.pdf0066-782XS0066-782X2006001900013http://repositorio.unifesp.br/handle/11600/3400porArquivos Brasileiros de Cardiologiainfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2024-08-05T20:51:07Zoai:repositorio.unifesp.br/:11600/3400Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-08-05T20:51:07Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
dc.title.none.fl_str_mv |
Função sistólica do ventrículo esquerdo pela ecocardiografia em crianças e adolescentes com osteossarcoma tratados com doxorrubicina com e sem dexrazoxane Left ventricular systolic function assessed by echocardiography in children and adolescents with osteosarcoma treated with doxorubicin alone or in combination with dexrazoxane |
title |
Função sistólica do ventrículo esquerdo pela ecocardiografia em crianças e adolescentes com osteossarcoma tratados com doxorrubicina com e sem dexrazoxane |
spellingShingle |
Função sistólica do ventrículo esquerdo pela ecocardiografia em crianças e adolescentes com osteossarcoma tratados com doxorrubicina com e sem dexrazoxane Matos Neto, Ranulfo Pinheiro de [UNIFESP] Left ventricular function echocardiography osteosarcoma doxorubicin dexrazoxane Função ventricular esquerda ecocardiografia osteossarcoma doxorrubicina dexrazoxane |
title_short |
Função sistólica do ventrículo esquerdo pela ecocardiografia em crianças e adolescentes com osteossarcoma tratados com doxorrubicina com e sem dexrazoxane |
title_full |
Função sistólica do ventrículo esquerdo pela ecocardiografia em crianças e adolescentes com osteossarcoma tratados com doxorrubicina com e sem dexrazoxane |
title_fullStr |
Função sistólica do ventrículo esquerdo pela ecocardiografia em crianças e adolescentes com osteossarcoma tratados com doxorrubicina com e sem dexrazoxane |
title_full_unstemmed |
Função sistólica do ventrículo esquerdo pela ecocardiografia em crianças e adolescentes com osteossarcoma tratados com doxorrubicina com e sem dexrazoxane |
title_sort |
Função sistólica do ventrículo esquerdo pela ecocardiografia em crianças e adolescentes com osteossarcoma tratados com doxorrubicina com e sem dexrazoxane |
author |
Matos Neto, Ranulfo Pinheiro de [UNIFESP] |
author_facet |
Matos Neto, Ranulfo Pinheiro de [UNIFESP] Petrilli, Antonio Sergio [UNIFESP] Silva, Célia Maria Campos [UNIFESP] Campos Filho, Orlando [UNIFESP] Oporto, Victor Manuel [UNIFESP] Gomes, Lourdes de Fátima Gonçalves [UNIFESP] Paiva, Marcelo Goulart [UNIFESP] Carvalho, Antonio Carlos [UNIFESP] Moisés, Valdir Ambrósio [UNIFESP] |
author_role |
author |
author2 |
Petrilli, Antonio Sergio [UNIFESP] Silva, Célia Maria Campos [UNIFESP] Campos Filho, Orlando [UNIFESP] Oporto, Victor Manuel [UNIFESP] Gomes, Lourdes de Fátima Gonçalves [UNIFESP] Paiva, Marcelo Goulart [UNIFESP] Carvalho, Antonio Carlos [UNIFESP] Moisés, Valdir Ambrósio [UNIFESP] |
author2_role |
author author author author author author author author |
dc.contributor.none.fl_str_mv |
Universidade Federal de São Paulo (UNIFESP) |
dc.contributor.author.fl_str_mv |
Matos Neto, Ranulfo Pinheiro de [UNIFESP] Petrilli, Antonio Sergio [UNIFESP] Silva, Célia Maria Campos [UNIFESP] Campos Filho, Orlando [UNIFESP] Oporto, Victor Manuel [UNIFESP] Gomes, Lourdes de Fátima Gonçalves [UNIFESP] Paiva, Marcelo Goulart [UNIFESP] Carvalho, Antonio Carlos [UNIFESP] Moisés, Valdir Ambrósio [UNIFESP] |
dc.subject.por.fl_str_mv |
Left ventricular function echocardiography osteosarcoma doxorubicin dexrazoxane Função ventricular esquerda ecocardiografia osteossarcoma doxorrubicina dexrazoxane |
topic |
Left ventricular function echocardiography osteosarcoma doxorubicin dexrazoxane Função ventricular esquerda ecocardiografia osteossarcoma doxorrubicina dexrazoxane |
description |
OBJECTIVE: To evaluate left ventricular (LV) systolic function by means of echocardiography in patients with osteosarcoma treated with doxorubicin alone or in combination with dexrazoxane. METHODS: The study analyzed 55 patients with osteosarcoma, with or without metastasis, undergoing a six-cycle chemotherapy regimen of doxorubicin, who were divided into two groups according to dexrazoxane use. Group I: Thirty-seven patients who did not receive dexrazoxane (28 males, average age 15.4 years). Group II: Eighteen patients who did receive dexrazoxane (15 males, average age 15.1 years). Four echocardiographic evaluations were performed: 1) before the beginning of the chemotherapy (initial evaluation); 2) up to two weeks after the third cycle; 3) up to two weeks after the fifth cycle; and 4) up to four weeks after the sixth cycle of chemotherapy (final evaluation). The left ventricular systolic function was assessed by the fractional percentage of systolic shortening (FS%) on echocardiography. Alterations in the contractile function or cardiac toxicity were defined as FS% values equal to or lower than 29%, and/or by a drop in FS% by an absolute value equal to or greater than 10 units of the baseline value of each patient. RESULTS: No significant difference as to age, gender, and race was observed between the groups. The cumulative dose of doxorubicin was significantly higher in group II throughout all phases of the treatment: 174 x 203 mg/m²; 292 x 338 mg/m² and 345 x 405 mg/² (p < 0.0001). According to previously established criteria, the incidence of LV systolic dysfunction was not significantly different (p=0.248) between patients in group I (18.92%) and patients in group II (11.1%). The variance analysis with repeated measurements did not show significant differences in the means of fractional percentage of systolic percentage (FS%) throughout the study (p=0.967). However, a significant difference (p=0.029) was observed between the FS% means in groups I and II at evaluations 2 (35.67 x 37.21%), 3 (34.95 x 38.47%) and 4 (35.26 x 38.22%). CONCLUSION: Data in this study show that in patients with osteosarcoma treated with doxorubicin alone or combined with dexrazoxane, the LV systolic function, as assessed by the fractional percentage of systolic shortening mean, showed a better performance in the group that received dexrazoxane. On the other hand, the occurrence of systolic dysfunction was similar in both groups. |
publishDate |
2006 |
dc.date.none.fl_str_mv |
2006-12-01 2015-06-14T13:36:34Z 2015-06-14T13:36:34Z |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.1590/S0066-782X2006001900013 Arquivos Brasileiros de Cardiologia. Sociedade Brasileira de Cardiologia - SBC, v. 87, n. 6, p. 763-771, 2006. 10.1590/S0066-782X2006001900013 S0066-782X2006001900013.pdf 0066-782X S0066-782X2006001900013 http://repositorio.unifesp.br/handle/11600/3400 |
url |
http://dx.doi.org/10.1590/S0066-782X2006001900013 http://repositorio.unifesp.br/handle/11600/3400 |
identifier_str_mv |
Arquivos Brasileiros de Cardiologia. Sociedade Brasileira de Cardiologia - SBC, v. 87, n. 6, p. 763-771, 2006. 10.1590/S0066-782X2006001900013 S0066-782X2006001900013.pdf 0066-782X S0066-782X2006001900013 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
Arquivos Brasileiros de Cardiologia |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
763-771 application/pdf |
dc.publisher.none.fl_str_mv |
Sociedade Brasileira de Cardiologia - SBC |
publisher.none.fl_str_mv |
Sociedade Brasileira de Cardiologia - SBC |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
instname_str |
Universidade Federal de São Paulo (UNIFESP) |
instacron_str |
UNIFESP |
institution |
UNIFESP |
reponame_str |
Repositório Institucional da UNIFESP |
collection |
Repositório Institucional da UNIFESP |
repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
repository.mail.fl_str_mv |
biblioteca.csp@unifesp.br |
_version_ |
1814268367218933760 |